UY25519A1 - Procedimiento para preparar antagonista del receptor de vitronectina - Google Patents
Procedimiento para preparar antagonista del receptor de vitronectinaInfo
- Publication number
- UY25519A1 UY25519A1 UY25519A UY25519A UY25519A1 UY 25519 A1 UY25519 A1 UY 25519A1 UY 25519 A UY25519 A UY 25519A UY 25519 A UY25519 A UY 25519A UY 25519 A1 UY25519 A1 UY 25519A1
- Authority
- UY
- Uruguay
- Prior art keywords
- phenyl
- preparing
- formula
- vitronectin receptor
- compounds
- Prior art date
Links
- 102100022337 Integrin alpha-V Human genes 0.000 title abstract 2
- 108010048673 Vitronectin Receptors Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 101100439665 Arabidopsis thaliana SWI2 gene Proteins 0.000 abstract 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- QQEIIOWLNXVJET-UHFFFAOYSA-N 4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-phenylbutanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=3C=CC=CC=3)=CC=2)=N1 QQEIIOWLNXVJET-UHFFFAOYSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Procedimiento para preparar compuestos farmacéuticamente activos de fórmula general (Ia) representada en la figura 1, o una sal farmacéuticamente aceptable del mismo, donde: X e Y son independientemente CR`R`, NR`o S; R1 es alquil C0-C6-het, alquil-C0-C6-Ar, -H, -CN, o -S(O)kR9; R2 es un grupo de los representados en la figura 2, donde W es -(CHR9)a-U-(CHR9)b-; el procedimiento comprende hacer reaccionar un compuesto de fórmula (IV) con un compuesto de fórmula (V), ambas representadas en la figura 3, con todos los grupos funionales protegidos, siendo L1 OH u halo, y luego sepearar todos los grupos protectores, y opcionalmente formar una sal farmacéuticamente aceptable. Ejemplos de compuestos de fórmula general: Ácido (+)-3-fenil-4-[3-(piridin-2-il)amino-1-prpiloxifenil]butanoico; Ácido de (+)-3-fenil-4-[4-[2-[6-(metilamino)-piridin-2-il]-1-etoxi]fenil]butanoico; entre otros. Estos compuestos inhiben el receptor de vitronectina y son útiles para el tratamiento de inflamación, cáncer y transtornos cardiovasculares, tales como arteriosclerosis y restenosis, y enfermedades en las que la resorción ósea es un factor, tal como la osteoporosis.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7761098P | 1998-03-10 | 1998-03-10 | |
| US9606398P | 1998-08-11 | 1998-08-11 | |
| UY25421A UY25421A1 (es) | 1998-03-10 | 1999-03-10 | Antagonistas de receptor de vitronectina |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25519A1 true UY25519A1 (es) | 1999-12-13 |
Family
ID=26759473
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25421A UY25421A1 (es) | 1998-03-10 | 1999-03-10 | Antagonistas de receptor de vitronectina |
| UY25519A UY25519A1 (es) | 1998-03-10 | 1999-05-19 | Procedimiento para preparar antagonista del receptor de vitronectina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25421A UY25421A1 (es) | 1998-03-10 | 1999-03-10 | Antagonistas de receptor de vitronectina |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1061921A4 (es) |
| JP (1) | JP2002506033A (es) |
| KR (1) | KR20010041812A (es) |
| CN (1) | CN1299282A (es) |
| AP (1) | AP2000001898A0 (es) |
| AR (1) | AR015241A1 (es) |
| AU (1) | AU758498B2 (es) |
| BG (1) | BG104824A (es) |
| BR (1) | BR9908636A (es) |
| CA (1) | CA2323208A1 (es) |
| CO (1) | CO5080762A1 (es) |
| DZ (1) | DZ2741A1 (es) |
| EA (1) | EA200000921A1 (es) |
| HU (1) | HUP0101143A3 (es) |
| ID (1) | ID26223A (es) |
| IL (1) | IL138245A0 (es) |
| NO (1) | NO20004503L (es) |
| OA (1) | OA12189A (es) |
| PE (1) | PE20000323A1 (es) |
| PL (1) | PL342881A1 (es) |
| SK (1) | SK13292000A3 (es) |
| TR (1) | TR200002625T2 (es) |
| UY (2) | UY25421A1 (es) |
| WO (1) | WO1999045927A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19939981A1 (de) * | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Neue Inhibitoren des Integrins alphavß3 |
| DE19939980A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitoren des Integrins alphavbeta¶3¶ |
| US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| US6448278B2 (en) | 1999-12-23 | 2002-09-10 | Pfizer Inc. | Procollagen C-proteinase inhibitors |
| GB9930570D0 (en) * | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
| FR2808798A1 (fr) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
| PE20020665A1 (es) | 2000-06-15 | 2002-08-14 | Pharmacia Corp | ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3 |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| US6645993B2 (en) | 2001-03-30 | 2003-11-11 | Warner-Lambert Company | 3-heterocyclylpropanohydroxamic acid PCP inhibitors |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| WO2005049589A2 (en) * | 2003-10-14 | 2005-06-02 | Cadila Healthcare Limited | Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases |
| BRPI0508397A (pt) * | 2004-03-05 | 2007-08-07 | Taisho Pharmaceutical Co Ltd | derivado de tiazol ou um sal farmaceuticamente aceitável do mesmo, inibidor de alk5, estimulador de proliferação de folìculo capilar, e, estimulador do crescimento capilar ou um agente de crescimento capilar |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| BRPI0610506A2 (pt) | 2005-04-20 | 2010-06-29 | Johnson & Johnson | moduladores de trombina de n-óxidos de piridina fluorados e processo para n-oxidação de heteroarilas contendo nitrogênio |
| PL3040329T3 (pl) * | 2013-08-29 | 2019-04-30 | Kyoto Pharma Ind | Związek aromatyczny i jego zastosowanie w leczeniu chorób związanych z metabolizmem kości |
| EP3929196B1 (en) | 2013-09-24 | 2023-08-23 | FUJIFILM Corporation | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof |
| MX2016015467A (es) | 2014-05-30 | 2017-03-23 | Pfizer | Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos. |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ203898A3 (cs) * | 1995-12-29 | 1999-03-17 | Smithkline Beecham Corporation | Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití |
| BR9612378A (pt) * | 1995-12-29 | 1999-07-13 | Smithkline Beecham Corp | Antagonistas receptores de vitronectina |
-
1999
- 1999-03-10 PE PE1999000188A patent/PE20000323A1/es not_active Application Discontinuation
- 1999-03-10 AR ARP990101019A patent/AR015241A1/es not_active Application Discontinuation
- 1999-03-10 UY UY25421A patent/UY25421A1/es unknown
- 1999-03-10 BR BR9908636-0A patent/BR9908636A/pt not_active Application Discontinuation
- 1999-03-10 CO CO99014712A patent/CO5080762A1/es unknown
- 1999-03-10 TR TR2000/02625T patent/TR200002625T2/xx unknown
- 1999-03-10 CN CN99805833A patent/CN1299282A/zh active Pending
- 1999-03-10 JP JP2000535342A patent/JP2002506033A/ja not_active Withdrawn
- 1999-03-10 WO PCT/US1999/005232 patent/WO1999045927A1/en not_active Ceased
- 1999-03-10 EA EA200000921A patent/EA200000921A1/ru unknown
- 1999-03-10 OA OA00000248A patent/OA12189A/en unknown
- 1999-03-10 HU HU0101143A patent/HUP0101143A3/hu unknown
- 1999-03-10 ID IDW20001737A patent/ID26223A/id unknown
- 1999-03-10 PL PL99342881A patent/PL342881A1/xx unknown
- 1999-03-10 EP EP99909952A patent/EP1061921A4/en not_active Withdrawn
- 1999-03-10 KR KR1020007010091A patent/KR20010041812A/ko not_active Withdrawn
- 1999-03-10 DZ DZ990042A patent/DZ2741A1/xx active
- 1999-03-10 SK SK1329-2000A patent/SK13292000A3/sk unknown
- 1999-03-10 AP APAP/P/2000/001898A patent/AP2000001898A0/en unknown
- 1999-03-10 CA CA002323208A patent/CA2323208A1/en not_active Abandoned
- 1999-03-10 IL IL13824599A patent/IL138245A0/xx unknown
- 1999-03-10 AU AU29033/99A patent/AU758498B2/en not_active Ceased
- 1999-05-19 UY UY25519A patent/UY25519A1/es unknown
-
2000
- 2000-09-08 NO NO20004503A patent/NO20004503L/no unknown
- 2000-10-03 BG BG104824A patent/BG104824A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR015241A1 (es) | 2001-04-18 |
| BG104824A (en) | 2001-05-31 |
| IL138245A0 (en) | 2001-10-31 |
| NO20004503D0 (no) | 2000-09-08 |
| CN1299282A (zh) | 2001-06-13 |
| UY25421A1 (es) | 2001-07-31 |
| AU2903399A (en) | 1999-09-27 |
| HUP0101143A2 (hu) | 2001-08-28 |
| OA12189A (en) | 2006-05-09 |
| CO5080762A1 (es) | 2001-09-25 |
| EP1061921A4 (en) | 2005-03-30 |
| HUP0101143A3 (en) | 2002-12-28 |
| TR200002625T2 (tr) | 2000-12-21 |
| PL342881A1 (en) | 2001-07-16 |
| SK13292000A3 (sk) | 2001-06-11 |
| EA200000921A1 (ru) | 2001-04-23 |
| CA2323208A1 (en) | 1999-09-16 |
| NO20004503L (no) | 2000-10-10 |
| DZ2741A1 (fr) | 2003-09-08 |
| JP2002506033A (ja) | 2002-02-26 |
| BR9908636A (pt) | 2002-01-08 |
| KR20010041812A (ko) | 2001-05-25 |
| AP2000001898A0 (en) | 2000-09-30 |
| ID26223A (id) | 2000-12-07 |
| EP1061921A1 (en) | 2000-12-27 |
| PE20000323A1 (es) | 2000-05-24 |
| WO1999045927A1 (en) | 1999-09-16 |
| AU758498B2 (en) | 2003-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25519A1 (es) | Procedimiento para preparar antagonista del receptor de vitronectina | |
| KR100850331B1 (ko) | 이온화 방사선 독성으로부터 세포 및 조직을 보호하는데 사용되는 약학적 조성물 | |
| NO20024217D0 (no) | 1,5-benzotiazepiner og deres anvendelse som hypolipidmidler | |
| CY1110382T1 (el) | Πυραζινο υποκατεστημενες αρυλοβενζοδιαζεπινες | |
| SE0203754D0 (sv) | New compounds | |
| AR029634A1 (es) | Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento | |
| KR950005817A (ko) | 5원환을 갖는 벤조-융합된 헤테로사이클릭 화합물, 이의 제조방법, 약제로서의 이의 용도, 진단제로서의 이의 용도 및 이를 함유하는 약제 | |
| AR017021A1 (es) | Acido 2-hidroxiacetico | |
| WO2002026712A3 (en) | Quaternary amines and related inhibitors of factor xa | |
| NO20050016L (no) | Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen | |
| ES2158778B1 (es) | Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen. | |
| DK1029853T3 (da) | Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler | |
| NO20051303L (no) | Nye benzoimidazolderivater nyttige som antiproliferative midler | |
| DOP2001000170A (es) | Derivados de tiofeno utiles como agentes anticancesoros | |
| ES2070126T3 (es) | Derivados de piridazinamina. | |
| NO992524L (no) | Konsenserte bicykliske pyrimidin-derivater | |
| GB9213623D0 (en) | Therapeutic agents | |
| PE20020721A1 (es) | Derivados de quinuclidina como agentes antimuscarinicos m3 | |
| WO2001056989A3 (en) | Inhibitors of factor xa | |
| NO20004281L (no) | 6,9-disubstituerte 2-[trans-(4-aminocykloheksyl)amino]puriner, farmasoytisk preparat inneholdende disse, og anvendelse derav for fremstilling av et medikament | |
| RU94045149A (ru) | Средство ингибирования легочных гипертонических заболеваний | |
| PT97395A (pt) | Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem | |
| PA8426801A1 (es) | Composiciones farmaceuticas para el tratamiento de la rinitis. | |
| ES2100222T3 (es) | Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas. | |
| WO2001057021A3 (en) | 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DESI | Application deemed to be withdrawn |
Effective date: 20071105 |